ABSTRACT Background: It is somewhat controversial whether caffeine consumption is associated with an increased risk of developing atrial fibrillation (AF). Objective: We prospectively assessed the relation between caffeine intake and incident AF. Design: A total of 33,638 initially healthy women who participated in the Women's Health Study and who were .45 y of age and free of cardiovascular disease and AF at baseline were prospectively followed for incident AF from 1993 to 2 March 2009. All women provided information on caffeine intake via food-frequency questionnaires at baseline and in 2004. Results: During a median follow-up of 14.4 y (interquartile range: 13.8-14.8 y), 945 AF events occurred. Median caffeine intakes across increasing quintiles of caffeine intake were 22, 135, 285, 402, and 656 mg/d, respectively. Age-adjusted incidence rates of AF across increasing quintiles of caffeine intake were 2.15, 1.89, 2.01, 2.24, and 2.04 events, respectively, per 1000 person-years of follow-up. In Cox proportional hazards models updated in 2004 by using time-varying covariates, the corresponding multivariableadjusted hazard ratios (95% CI) were 1.0, 0.88 (0.72, 1.06), 0.78 (0.64, 0.95), 0.96 (0.79, 1.16), and 0.89 (0.73, 1.09) (P for linear trend: 0.45). None of the individual components of caffeine intake (coffee, tea, cola, and chocolate) were significantly associated with incident AF. Conclusions: In this large cohort of initially healthy women, elevated caffeine consumption was not associated with an increased risk of incident AF. Therefore, our data suggest that elevated caffeine consumption does not contribute to the increasing burden of AF in the population. This trial was registered at clinicaltrials.gov as NCT00000479.
INTRODUCTION
In recent years, several issues have been clarified with regard to cardiovascular health effects of caffeine, a widely consumed substance with stimulating effects. For example, recent studies disconfirmed earlier concerns that coffee consumption may increase the risk of coronary artery disease or stroke (1) (2) (3) . There is also increasing evidence that coffee consumption does not confer a greater risk of incident hypertension (4) and may even protect from type 2 diabetes (5).
Many patients with paroxysmal atrial fibrillation (AF) indicate coffee intake as a triggering factor for arrhythmia (6) , and there is a fairly widespread belief that caffeine intake is related to the development of AF. Nevertheless, little information is available to support this assumption. An association between caffeine intake and AF would be of substantial public health relevance given the widespread consumption of caffeine-containing beverages and the high prevalence of AF in the general population (7) (8) (9) (10) and its associated comorbidities (11) (12) (13) (14) (15) .
The majority of data in support of the association are derived from retrospective analyses (16) , which are subject to recall bias. The only prospective study published so far suggested that caffeine consumption was not associated with hospitalizations for AF in a population with high caffeine intake (17) . In experimental animal models, intravenous caffeine administration actually reduced the propensity for AF (18) . With consideration of these controversial data and the relative lack of prospective information, we further addressed this issue by prospectively examining the relation between caffeine consumption and incident AF in a large cohort of initially healthy women with a broad range of caffeine intake.
SUBJECTS AND METHODS

Participants
All study participants were enrolled in the Women's Health Study, a completed randomized trial that evaluated the risks and benefits of low-dose aspirin and vitamin E in the primary prevention of cardiovascular disease and cancer. Details of the study design have been described previously (19) (20) (21) . Briefly, beginning in 1993, 39,876 female health professionals in the United States who were age 45 y old and free of cardiovascular disease, cancer, or other major illnesses were randomly assigned to receive 100 mg aspirin every other day, 600 IU vitamin E every other day, both agents, or a placebo. Randomized treatment ended on 31 March 2004, and women were invited to participate in continued observational follow-up, which for the current analysis was truncated on 2 March 2009. Of the original cohort, 4324 women opted out of the observational follow-up. These women were excluded from this analysis because their AF could not be reliably confirmed. However, our findings were very similar in a sensitivity analysis that used self-reported AF events in all women as the main outcome variable to ensure that exclusion of these women did not significantly alter our results (data not shown).
We also excluded 1907 women because they either had a history of AF at baseline or did not provide information on beverages and diet, had implausible total energy intakes (,600 or .3500 kcal/d), or left .70 items blank on the food-frequency questionnaire (FFQ) and 7 women because they were subsequently diagnosed with cardiovascular disease before randomization. The final study population for this analysis consisted of 33,638 women. Written informed consent was obtained from all participants. The study was approved by the institutional review board of the Brigham and Women's Hospital (Boston, MA) and was monitored by an external data and safety monitoring board.
Assessment of caffeine intake
At baseline, 39,310 women (98.6%) in the Women's Health Study completed a 131-item FFQ, a format that was used and validated in the Nurses' Health Study (22) (23) (24) . In 2004, 29,633 (88%) of the 33,638 women included in the current analysis completed a second FFQ. The questionnaire assessed average consumption during the previous year of a specific amount of foods, including coffee, decaffeinated coffee, tea, caffeinated cola, decaffeinated cola, low-calorie caffeinated cola, low-calorie decaffeinated cola, and chocolate, and allowed 9 responses that ranged from never to 6 times/d. Intakes of nutrients and caffeine consumption were calculated by using the US Department of Agriculture food composition data (25) and supplemented by food manufacturers. In these calculations, we assumed that the content of caffeine was 137 mg/cup of coffee, 47 mg/cup of tea, 46 mg/can or bottle of cola, and 7 mg/serving of chocolate candy (4, 26) . Validation studies in the Nurses' Health Study revealed high correlations between self-reported intakes of coffee and other caffeinated beverages assessed by the FFQ and by 4 wk of diet records (r = 0.78 for coffee, r = 0.93 for tea, and r = 0.85 for caffeinated sodas) (22) . Coffee was the primary source of caffeine intake (81.3%), with fewer contributions by tea (10.0%), low-calorie caffeinated cola (5.6%), caffeinated cola (1.2%), chocolate (0.3%), and other foods (1.7%).
Information on all baseline variables was collected by using mailed questionnaires. Follow-up questionnaires that asked participants about study outcomes and other information were sent every 6 mo during the first year and every 12 mo thereafter. Covariates of interest were self-reported at study entry and included age, body mass index (weight in kilograms divided by the square of height in meters), smoking, blood pressure, history of hypertension, history of hypercholesterolemia, diabetes, parental history of myocardial infarction, alcohol consumption, fish consumption, exercise, and race-ethnicity, which was selfreported by the participants as white, black, Hispanic American, Asian American, or other. We updated information for all relevant covariates at the time of the second FFQ administration.
Ascertainment of incident AF
Details about the confirmation of AF in the Women's Health Study have been reported previously (27, 28) . In brief, women enrolled in the continued observational follow-up who reported an incident AF event on at least one yearly questionnaire were sent an additional questionnaire to confirm the episode and collect additional information. The women were also asked for permission to review their medical records. For all deceased participants who reported AF during the trial and extended follow-up period, we contacted family members to obtain consent and additional relevant information. An endpoint committee of physicians reviewed medical records for reported events according to predefined criteria. An incident AF event was confirmed if there was electrocardiographic evidence of AF or if a medical report clearly indicated a personal history of AF.
Statistical analyses
We used Spearman correlations to assess the correlation between energy-adjusted caffeine intakes from the 2 FFQs. The main analyses assessed the association between quintiles of caffeine intake and incident AF. Age-and multivariable-adjusted Cox proportional hazards models were constructed to compare hazard ratios and 95% CIs across quintiles of caffeine consumption. For each woman, person-years of follow-up were calculated from the date of return of the baseline questionnaire to the date of first endpoint, death, last follow-up, or to 2 March 2009, whichever came first. Covariates for multivariable models included age, systolic blood pressure, body mass index, hypertension, diabetes, hypercholesterolemia, smoking, exercise, alcohol consumption, parental history of myocardial infarction, treatment group, fish intake, and race-ethnicity. Caffeine intake and other covariates were included in the models as time-varying covariates and updated at the date of the second FFQ in 2004 whenever appropriate. For the 4005 women who did not return the second FFQ, we carried forward their reported caffeine intake at baseline. Women in the lowest category of caffeine consumption were chosen as the reference group for all analyses. In secondary analyses, we assessed the relation between the individual sources of caffeine intake and risk of incident AF, namely caffeinated coffee, decaffeinated coffee, tea, caffeinated cola, decaffeinated cola, low-calorie caffeinated cola, low-calorie decaffeinated cola, and chocolate.
Tests for linear and quadratic trends were performed by assigning women the quintile-specific median value of caffeine intake. We tested for deviation from linearity by including quadratic terms in the trend models. We used indicator variables for all covariates that were missing (,2% of missing values for any variable). All analyses were carried out with SAS version 9 software (SAS Institute Inc, Cary, NC). A 2-tailed P ,0.05 indicated statistical significance. P values were not adjusted for multiple testing.
RESULTS
Median caffeine consumption at baseline across increasing quintiles of caffeine intake was 22, 135, 285, 402, and 656 mg/d, respectively. Baseline characteristics stratified by increasing quintiles of caffeine consumption are shown in Table 1 . Women with elevated caffeine consumption smoked more often and consumed more alcohol, but they had a lower prevalence of hypertension and type 2 diabetes. Caffeine intakes between the 2 FFQs were significantly correlated (r = 0.55, P , 0.001).
During a median (interquartile range) follow-up of 14.4 y (13.8-14.8 y), 945 confirmed AF events occurred. Age-adjusted incidence rates for AF showed little variation across quintiles of caffeine consumption, between 1.89 events/1000 person-years in women in the second quintile and 2.24 events/1000 person-years in women in the fourth quintile ( Table 2) . Age-adjusted Cox proportional hazards models confirmed the absence of a greater AF risk in women who consumed high amounts of caffeine (P for linear trend: 0.44) and suggested a U-shaped association with the lowest risk in women in the third quintile of caffeine intake (median: 285 mg/d; P for quadratic trend: 0.03). These associations remained virtually unchanged after comprehensive multivariable adjustment, as shown in Table 2 (P for linear trend: 0.45; P for quadratic trend: 0.01). Our results were not appreciably altered when we excluded women who reported a cardiovascular event before the occurrence of AF (data not shown).
In secondary analyses, we did not find any linear association between different sources of caffeine intake assessed separately and risk of AF, as shown in Table 3 . However, women in the fourth quintile of caffeinated-coffee consumption had an increased risk of incident AF compared with women in the lowest quintile [hazard ratio (95% CI): 1.36 (1.12, 1.65) ], but no clear dose-response relation was observed because the risk in women in the highest quintile of caffeinated coffee consumption was not increased [hazard ratio (95% CI): 1.03 (0.79, 1.35)] (Table 3) . Adding a quadratic term to the trend models improved the model fit for caffeinated coffee (P = 0.01) but not for decaffeinated coffee (P = 0.32), which suggested a potential curvilinear relation between caffeinated coffee and incident AF.
DISCUSSION
In this prospective study, caffeine consumption was not associated with an increased risk of incident AF in initially healthy, middle-aged women. Women in the highest quintile of caffeine consumption had a similar risk of developing AF during follow-up compared with women in the lowest quintile, and The lack of elevation in AF risk associated with higher amounts of caffeine consumption is consistent with findings from the prospective Danish, Diet, Cancer, and Health Study in which no association between a single measure of caffeine intake and AF was shown in 47,949 men and women who were not previously hospitalized for endocrine or cardiovascular disease (17) . The current study extends these findings to much lower amounts of caffeine intake. Our study also differs in that the Danish study assessed only AF hospitalizations and few of these events occurred in women.
The lack of an increased AF risk associated with elevated caffeine intake observed in these 2 studies is also in accordance with experimental studies. Acute caffeine ingestion had no effect on P-wave duration and dispersion in healthy volunteers (29, 30) , which are both electrocardiographic markers of AF risk (31) . Caffeine intake did not have an effect on interatrial and intraatrial conduction intervals when assesses invasively by electrophysiologic testing (32) , and intravenous caffeine resulted in a lower window of vulnerability, a measure of the propensity for AF inducibility, in an experimental dog model (18) . Finally, coffee and tea, the major sources of caffeine intake also contain polyphenols and other antioxidative ingredients (33) that may be protective against AF (34) .
With respect to the individual sources of caffeine, we cannot rule out the possibility that moderate amounts of caffeinatedcoffee consumption (2-3 cups/d) are associated with elevated risks of AF. Similar findings were obtained in a Swedish study of middle-aged men, where men who consumed 1-4 cups of coffee/d had a hazard ratio for incident AF of 1.24 (95% CI: 1.00, 1.54) compared with men who did not drink coffee (35) . In both studies, risks were not elevated in those with higher amounts of intake, which suggests that the association may be curvilinear. However, we did not find a similar association for decaffeinated coffee, and given the number of comparisons and the lack of known biologic plausibility for such a curvilinear relation, chance or residual confounding provides a likely alternative explanation for these findings.
Strengths of the current study include the prospective design, sample size, long-term follow-up with a large number of confirmed events, and the possibility of updating caffeine consumption during follow-up. On the other hand, a number of potential limitations need to be considered in the interpretation of our findings. First, if caffeine intake influences AF risk only through short-term mechanisms, we may have been unable to detect an association by using only 2 measures of caffeine intake several years apart. Retrospective case-control studies, which measure caffeine intake closer to the event, reported associations between elevated coffee consumption and the first episode of AF (16) . However, such retrospective studies are significantly limited by recall bias because many patients consider coffee intake as a triggering factor (6). Our prospective design reduced such recall bias, and the relatively high correlation of caffeine intake between the 2 questionnaires (r = 0.55) suggested that caffeine intake may not vary to a large degree over time. Therefore, our isolated measures may be a reasonable proxy for recent intake. Second, we included initially healthy, middle-aged, female health professionals, and most of them were of white origin. Thus, generalizability to men or other female populations may be limited. Third, some of the beverage subgroups were small, and we had limited statistical power to find true associations in these subgroups. Fourth, screening electrocardiograms were not performed in this cohort, and it is possible that asymptomatic AF cases may have gone undetected. However, the number of asymptomatic AF cases in this cohort of health professionals (n = 99; 10.5%) was similar to the number of cases detected by screening electrocardiograms in other cohorts (36, 37) . Finally, defining the initial episode of AF accurately is challenging, and misspecification of the time of incidence may have introduced some bias toward the null in the time-to-event analysis. Given the small number of events, this bias would be expected to be small.
In conclusion, elevated caffeine consumption did not confer an increased risk of incident AF in this large cohort of initially healthy women. By contrast, pending confirmation by other prospective studies, the consumption of small to moderate amounts of caffeine may have a small but significant protective effect on the occurrence of AF. Our data, in combination with prior prospective studies, suggest that elevated consumption of caffeine does not contribute to the increasing burden of AF in the general population.
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